PMID- 28699798
OWN - NLM
STAT- MEDLINE
DCOM- 20180313
LR  - 20221207
IS  - 1473-4877 (Electronic)
IS  - 0300-7995 (Linking)
VI  - 33
IP  - 9
DP  - 2017 Sep
TI  - Durability of response to dapagliflozin: a review of long-term efficacy and 
      safety.
PG  - 1685-1696
LID - 10.1080/03007995.2017.1354822 [doi]
AB  - BACKGROUND: Due to the chronic nature of type 2 diabetes (T2D), it is essential 
      for an anti-diabetic drug to have durable efficacy and a good long-term safety 
      profile. Dapagliflozin is a member of a unique class of anti-diabetic drugs that 
      inhibit the sodium-glucose cotransporter 2 (SGLT-2) in the renal tubules and have 
      an insulin-independent mechanism of action. In short-term studies (</= 24 weeks), 
      dapagliflozin reduced glycated hemoglobin (A1c), weight, and systolic blood 
      pressure, and had a good safety profile. METHODS: This review summarizes the 
      findings of long-term studies that evaluated the efficacy and safety of 
      dapagliflozin. RESULTS: These findings indicate that dapagliflozin is effective 
      as monotherapy and in combination with other anti-hyperglycemic agents, including 
      insulin and oral anti-diabetic therapies, in improving glycemic control and 
      reducing blood pressure and weight for up to 4 years. The findings were fairly 
      consistent across various patient populations with T2D, including those with 
      cardiovascular disease (CVD) and mild renal impairment. Extended use of 
      dapagliflozin was not associated with an increase in safety signals over time. 
      Frequently observed adverse events (AEs) were consistent with the drug's 
      mechanism of action and were generally mild in intensity. No substantial impact 
      of dapagliflozin on renal function was observed, and findings show that the drug 
      is safe in T2D patients with CVD or mild renal impairment, as well as elderly 
      patients. CONCLUSIONS: The findings across the studies support the use of 
      dapagliflozin for the long-term treatment of T2D across a broad spectrum of 
      patients.
FAU - Jabbour, Serge
AU  - Jabbour S
AD  - a Sidney Kimmel Medical College at Thomas Jefferson University , Philadelphia , 
      PA , USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20170731
PL  - England
TA  - Curr Med Res Opin
JT  - Current medical research and opinion
JID - 0351014
RN  - 0 (Benzhydryl Compounds)
RN  - 0 (Blood Glucose)
RN  - 0 (Glucosides)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Insulin)
RN  - 0 (SLC5A2 protein, human)
RN  - 0 (Sodium-Glucose Transporter 2)
RN  - 0 (Sodium-Glucose Transporter 2 Inhibitors)
RN  - 1ULL0QJ8UC (dapagliflozin)
SB  - IM
MH  - Benzhydryl Compounds/*therapeutic use
MH  - Blood Glucose/drug effects
MH  - Blood Pressure/drug effects
MH  - Cardiovascular Diseases/complications
MH  - Diabetes Mellitus, Type 2/*drug therapy
MH  - Glucosides/*therapeutic use
MH  - Glycated Hemoglobin/drug effects
MH  - Humans
MH  - Hypoglycemic Agents/*therapeutic use
MH  - Insulin/metabolism
MH  - Renal Insufficiency/complications
MH  - Sodium-Glucose Transporter 2
MH  - Sodium-Glucose Transporter 2 Inhibitors
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Diabetes mellitus
OT  - SGLT-2 inhibitor
OT  - dapagliflozin
OT  - efficacy
OT  - safety
OT  - treatment
OT  - type 2
EDAT- 2017/07/13 06:00
MHDA- 2018/03/14 06:00
CRDT- 2017/07/13 06:00
PHST- 2017/07/13 06:00 [pubmed]
PHST- 2018/03/14 06:00 [medline]
PHST- 2017/07/13 06:00 [entrez]
AID - 10.1080/03007995.2017.1354822 [doi]
PST - ppublish
SO  - Curr Med Res Opin. 2017 Sep;33(9):1685-1696. doi: 10.1080/03007995.2017.1354822. 
      Epub 2017 Jul 31.